For example, if a patient was receiving an OAP from day 1 to day 90 and started an LAI Q1M from day 60 to day 360, then this patient would contribute two treatment periods from day 1 to day 360 (i.e., OAP period from day 1 to day 90 and LAI Q1M from day 60 to 360)
Key Takeaways Legal protection through documented informed consent and risk acknowledgment Comprehensive contraindication screening prevents adverse events Patient education ensures realistic expectations for B12 therapy Post-injection care guidance supports compliance and recovery Digital signature integration streamlines clinic workflows A b12 injection consent form is a clinical documentation tool that educates patients about intravenous B-12 and amino acid injection therapy while establishing legal protection for your practice
It is a compounded peptide available only through licensed providers
It is typically thought to be well tolerated in animal research
Scientific and Official Sources PubChem: BPC-157 identity, synonyms, molecular formula and mass Sikiric and colleagues: early published BPC-157 research ClinicalTrials.gov: PCO-02 BPC-157 safety and pharmacokinetics study Lee and colleagues: two-participant BPC-157 intravenous pilot study McGuire and colleagues: narrative review of BPC-157 evidence and risk World Anti-Doping Agency: 2026 Prohibited List MHRA: Borderline products and how to tell if a product is a medicine Human Medicines Regulations 2012: Regulation 279 United States FDA: safety risks associated with certain bulk substances, including BPC-157 United States FDA: BPC-157-related bulk-substance briefing document CAP Code Section 12: Medicines and health-related products Health and Safety Executive: UK REACH Health and Safety Executive: Safety Data Sheets and COSHH Health and Safety Executive: COSHH risk assessment Cox and colleagues: identification and analytical detection of BPC-157 in confiscated material
Additive Effect of Apicidin and Doxorubicin in Sulfatase 1 Expressing Hepatocellular Carcinoma In Vitro and In Vivo
